financetom
Business
financetom
/
Business
/
Specialty vehicle insurer Hagerty beats Q3 estimates, hikes FY forecast
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Specialty vehicle insurer Hagerty beats Q3 estimates, hikes FY forecast
Nov 4, 2025 4:27 AM

Overview

* Hagerty Q3 2025 revenue grows 18% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting strong performance

* Company raises 2025 outlook for revenue, net income, and adjusted EBITDA growth

Outlook

* Hagerty ( HGTY ) raises 2025 total revenue growth outlook to 14-15%

* Company expects 2025 net income growth of 58-65%

* Hagerty ( HGTY ) anticipates 2025 adjusted EBITDA growth of 37-41%

Result Drivers

* MARKETPLACE REVENUE - Q3 Marketplace revenue increased 58% yr/yr, driven by higher inventory sales and European auctions

* OPERATING INCOME SURGE - Operating income rose 240% yr/yr, attributed to expanded margins and cost discipline

* PARTNERSHIP WITH LIBERTY MUTUAL - New partnership with Liberty Mutual, the seventh largest auto insurer in the US, expected to enhance market position

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $380 mln $354.74

Revenue mln (5

Analysts

)

Q3 Beat $0.13 $0.07 (7

Adjusted Analysts

EPS )

Q3 Net $46.20

Income mln

Q3 Beat $49.70 $40.54

Adjusted mln mln (6

EBITDA Analysts

)

Q3 EBIT $34.30

mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the property & casualty insurance peer group is "buy."

* Wall Street's median 12-month price target for Hagerty Inc ( HGTY ) is $13.50, about 16.4% above its November 3 closing price of $11.29

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Southwest flight takeoff canceled after crew mistook Orlando taxiway for runway
Southwest flight takeoff canceled after crew mistook Orlando taxiway for runway
Mar 20, 2025
WASHINGTON, March 20 (Reuters) - A Southwest Airlines ( LUV ) flight aborted takeoff at Orlando airport on Thursday after it mistakenly began to depart on a taxiway rather than the runway, the latest in a series of recent incidents that have raised concerns about U.S. aviation safety. An air traffic controller at the Florida airport canceled the takeoff clearance...
BRIEF-Aspen Insurance Holdings Ltd Sees U.S. IPO Of Class A Ordinary Shares
BRIEF-Aspen Insurance Holdings Ltd Sees U.S. IPO Of Class A Ordinary Shares
Mar 20, 2025
March 20 (Reuters) - * ASPEN INSURANCE HOLDINGS LTD SEES U.S. IPO OF CLASS A ORDINARY SHARES- SEC FILING ...
Brazilian cosmetics group Natura to revamp structure, leadership
Brazilian cosmetics group Natura to revamp structure, leadership
Mar 20, 2025
SAO PAULO, March 20 (Reuters) - Brazilian cosmetic group Natura announced on Thursday a leadership shake up as well as a restructuring proposal that would change out the entity that is listed on the local stock exchange. Under the plan, set to be voted on by shareholders on April 25, the currently listed holding company Natura&Co will be integrated into...
US FDA expands approval for Alnylam's drug to treat rare heart disease
US FDA expands approval for Alnylam's drug to treat rare heart disease
Mar 20, 2025
* Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM * Pricing strategy crucial for Amvuttra's market share against oral options (Adds executive comments in paragraph 4, rival treatment prices in paragraphs 9 and 10) By Bhanvi Satija and Sneha S K March 20 (Reuters) - U.S. Food and Drug Administration approved Alnylam's drug to treat a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved